This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 5
  • /
  • Marketing Authorization applications for proposed ...

Marketing Authorization applications for proposed biosimilar denosumab accepted by EMA

Read time: 1 mins
Published:25th May 2023

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the European Medicines Agency (EMA) has accepted the marketing authorization applications (MAA) for proposed biosimilar denosumab for regulatory review

The two applications include all indications covered by the reference medicines Prolia (denosumab) and Xgeva (denosumab), respectively, for treating a variety of conditions, including osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that have spread to the bone, and giant cell tumor of the bone.

“Sandoz is one of the first to have its applications for a proposed biosimilar denosumab accepted by the EMA. If approved, this has the potential to provide people living with osteoporosis and cancer of the bone or bone metastasis access to a cost-effective and high-quality treatment option.” said Florian Bieber, Development Platform Head Biopharmaceuticals and Chief Medical Officer, Sandoz. “This news follows the recent application acceptance by the US Food and Drug Administration and supports our continued commitment to providing expanded access to life-changing treatments, while also helping over-burdened healthcare systems generate savings.”

Approximately 500 million men and women worldwide may be affected by osteoporosis, which causes 8-9 million fractures annually – or one fracture every three seconds. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 1990. Prevalence of skeletal related complications in cancer is estimated to be as high as 63% for breast cancer, 59% for lung cancer and 52% for prostate cancer. Skeletal related complications in cancer are associated with loss of mobility and social functioning, reduced quality of life, increased health care expenditure and worse survival.

Condition: Osteoporosis and related conditions
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights